Susanne Coleman

Dr Susanne Coleman, University of Leeds, TVS Speaker

A nurse for older people by background, Susanne has worked across primary care, secondary care and voluntary sectors, leading multi-disciplinary organisational change/development, transitioning in the last 12 years to a research career.

Susanne is an NIHR Post-doctoral research fellow, key member of the Skin Portfolio academic team of the Surgical Interventions, Diagnostics and Devices (SIDD) division, at Leeds Institute Clinical Trials Research (LICTR) and a founding member of the Leeds Unit for Complex Intervention Development (LUCID,) at the University of Leeds.

Susanne used her substantive applied health research experience as part of the NIHR PURPOSE Programme (RP-PG-0407-10056) and HTA PRESSURE-2 trial (11/36/33) to establish an internationally recognised portfolio of Pressure Ulcer research.

As a post-doctoral researcher she has a growing reputation as a qualitative and mixed methods researcher incorporating consensus methods, cognitive pre-testing methods, realist methodologies, innovative service user involvement and intervention development/evaluation with 6 funded awards (1 NIHR Development Grant (RP-DG-0218-10001), 2 NHS National Wound Studies, a European core outcome set study, 2 personal NIHR Fellowship scheme awards (Post-doc and DSE).

Presentation at the WReN Scientific Meeting, Glasgow, May 2022

Pressure ulcer risk assessment – barriers and levers to national and international implementation


After attending this session, persons will be able to:

  • Understand the need for evidenced-based pressure ulcer risk assessment
  • Know where to gain further information about PURPOSE-T and supporting evidence
  • Consider barriers and levers for evidenced-based pressure ulcer risk assessment in clinical practice

Abstract – The need for an evidenced-based Pressure Ulcer Risk Assessment Instrument was identified following a risk factor systematic review and a review of the content, development, testing and practical use of existing RAIs (1). This work identified limitations in instrument development methods, raising concern about their content validity and use in clinical practice.

PURPOSE-T was developed as part of an NIHR funded Research Programme (PURPOSE: RP-PG-0407-10056) using adapted ‘gold standard’ instrument development methods (1). PURPOSE-T is different to other RAIs as it incorporates a screening stage; a full assessment stage; the use of colour to support decision-making; and decision pathways, which make a distinction between patients with an existing PU(s) who require secondary prevention/treatment and those at risk who require primary prevention. It incorporates skin status and perfusion, important risk factors which are not universally incorporated into RAIs.

PURPOSE-T has since been implemented into routine care in acute and community Trusts and hospice settings with barriers and levers to implementation identified throughout the process. Evaluation of its impact on processes of care and outcomes is ongoing, with methods being adapted due to the COVID pandemic.

Acknowledgement – This presentation presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (RP-PG-0407-10056). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

References – PURPOSE Monograph, Nixon2015